Primary Biliary Cholangitis clinical trials at UCSF
2 research studies open to eligible people
Showing trials for
Global Linerixibat Itch Study of Efficacy and Safety in Primary Biliary Cholangitis (PBC) (GLISTEN)
open to eligible people ages 18-80
This is a 2-part study in PBC participants with cholestatic pruritus and will evaluate the efficacy, safety and impact on health-related quality of life of linerixibat compared with placebo.
San Francisco, California and other locations
Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
open to eligible people ages 18-75
To Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients with Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis.
San Francisco, California and other locations
Our lead scientists for Primary Biliary Cholangitis research studies include Monika Sarkar.
Last updated: